[Abstract] For three days of 2021 national medical insurance drug catalog negotiations in Beijing, the final result is expected to announce in November.
A three-day 2021 national medical insurance drug catalog negotiations in Beijing, the final result is expected to announce in November.The National Medical Insurance Bureau issued the 20021 National Medical Pharmaceutical Directory Adjustment By the preliminary form review, a total of 271 drugs this year passed the initial form of review, of which the new listing of newly listed after 2016.According to the National Medical Insurance Bureau, as the first CAR-T cell theraser in China, Akun injection of more than one million yuan (12 million yuan / needle, anti-cancer) is just approved in June this year, although appearingIn 2021, the national medical insurance drug catalog adjustment passed the preliminary formal review of the drug list, but did not enter the medical insurance catalog negotiation.
The relevant person in charge of the National Medical Insurance Bureau introduced that drugs were more expensive, and only the preliminary form of review was preliminaryly, and the drug was in accordance with the application conditions, the qualification of the next adjustment process was obtained. According to the "2021 National Medical Insurance Drug Directory, the directory adjustment includes the preparation, declaration, review, negotiation, announcement of the results and other stages.
Such medicines can ultimately enter the national medical insurance drug catalog, but also accept strict reviews including economics, and exclusive drugs should also be negotiated. At present, my country’s basic medical insurance fundraising levels, especially urban and rural residents, and the current basic medical insurance system in the overall development of medical insurance systems, the treatment of medical insurance funds, and the level of anti-risk capacity of medical insurance funds. It is mainly based on providing basic disease treatment for the masses, focusing on meeting the basic medical needs of the masses. In the adjusted drug catalog adjustment, the State Medical Insurance Bureau has always firmly grasped the functional positioning of basic medical insurance "basic", focusing on the clinical value, reasonable price, and can meet the drugs that can meet basic medical needs.
Since 2000, the national medical insurance drug catalog has been adjusted six times, and the number of drugs in the catalog increased from 1535 to 2,800, and the medical security scope is further expanded while optimizing the medical insurance catalog structure.
The National Medical Insurance Bureau said that solving the availability of new drugs can only rely on basic medical insurance, and you can give full play to the channel functions of various supplementary insurance, commercial health insurance, and better through the establishment of a multi-level medical security system that improves Chinese characteristics. Meet different levels of medication requirements. According to Xinhua News Agency, the average price reduction of drugs last year is based on the initial estimate of the media. The national medical insurance drug catalog has been adjusted in three years. Compared with the market price of negotiations, it is adjusted to negotiate price reduction and medical insurance reimbursement. The beneficiary patients reached 100 million. 2020 medical insurance negotiations successful drugs, average price reduction%.
The climax of medical insurance negotiations is the mutual game of the medical insurance bureau and pharmaceutical enterprises.
In 2019, the video of the medical insurance negotiations in Zhejiang Province has been widely circulated. After the price of the soul of the medical insurance bureau, after the price will cut the price from Yuan, the experts said: "Yuan’s words, 4 too many Chinese people feel difficult to listen , Then drop 4 points, do not work, "The medicine for medical insurance negotiations is the Damura net (Anda Tang), which is a" benchmark "for treating type 2 diabetes. At the beginning of the negotiation, the medical insurance bureau staff will open from Cheng Gong: "There is twice in the quotation. If the quotation does not meet our psychological price, then he will go out." "It is a bit far from the target price." The representative of the pharmaceutical enterprises repeatedly walked out of the venue and called quoted with the rear. In the end, pharmaceutical companies agreed to pay by Yuandu, this is the "lowest price". In 2021, medical insurance negotiations were shared 3 days, and 4 meeting rooms were divided. According to incomplete statistics, the first day of negotiations, there is a total of Hansen Pharmaceuticals, Haisco, Roche, Stone Medicine, Merzandon, Hai Zheng, Jiangsu Eddy, Yichang, Hengrui, Novoord, Geely, Shandong Thai, More than 20 companies in the Yangtze River, GSK, Songs, Aslikang, Dongyang, Novartis, Sino-US East, Yingu Pharmaceutical, etc. According to CCTV financial news, the medical insurance negotiations, a total of 25 experts were divided into 5 groups of 120 or more drugs. According to this estimation, in the 271 preliminary form review directory, the pass rate has exceeded%, higher than the pass rate of% by 2020. The "bargain" on-site negotiation drug’s bottom price "Tibet" on November 11 in the envelope, the medical insurance negotiation enters the third day.
In the Beijing hotel hall in Beijing, the atmosphere is still nervous.
National medical insurance negotiations have strict confidentiality measures.
According to the previously announced on-site information, the negotiating experts representing the National Medical Insurance Bureau and the company representatives are relatively, and one envelope is installed in an envelope in the site, that is, the industry called "letter package".
This "letterpoint price" is the price that has been calculated by medical insurance experts and health economics experts, and is the secret of medical insurance negotiations.
The medical insurance experts open the sealed envelope to know the price and medical insurance base price to negotiate on the spot on the day.
After entering the negotiation site, the company will enter the "letterpoint price" 115% before it can be finalized to enter the two parties.
The business representative does not know the expected price of the medical insurance bureau. For the quotation, it should be cautious; the medical insurance experts can not reveal the "bottom card" in their hands, but also to guide the company to report the expected price.
The medical insurance negotiations are successful for corporate representatives, which means drug price cuts, but also to get more market sales by entering the medical insurance catalog, therefore the representatives of entering the on-site negotiation are quite important.
The negotiated business representatives have stepped away from the scene, and they rejected the call questions from all vendors. It is also a renewal, some companies are a bit "pressure mountain". In a brief chat with reporters, a representative from the Chinese medicine company from Hebei said that in recent years, the newly batch of traditional Chinese medicine is particularly small. This time, the pressure is relatively large, but still needs to wait until you finish, it is expected.
He mentioned that when he just said in 2019, the drug price was very large.
As for the specific data, the pharmaceutical representative responded: "Don’t say it." And according to another representative of this pharmaceutical enterprise, when he talks about new drugs last year, the price has also dropped a lot, down 50%. Comprehensive CCTV and other sources: Hua Shang.com – China Business News.